Predicting Success and Failure on Long-acting Cabotegravir/Rilpivirine
Daniel R. Kuritzkes, MD
Professor, Harvard Medical School
Chief, Division of Infectious Diseases
Brigham and Women's Hospital, Boston, MA
Videos of live meetings of PRN in NYC are owned and published by Physicians’ Research Network, Inc. Copyright © 2022. All rights reserved.
Daniel R. Kuritzkes, MD received his BS and MS degrees in Molecular Biophysics and Biochemistry from Yale University, and his MD from Harvard Medical School. He completed his clinical and research training in internal medicine and infectious diseases at Massachusetts General Hospital and was a visiting scientist at the Whitehead Institute for Biomedical Research before joining the faculty at the University of Colorado Health Sciences Center. Dr. Kuritzkes returned to Harvard Medical School in 2002, where he is now the Harriet Ryan Albee Professor of Medicine and Chief, Division of Infectious Diseases at Brigham and Women’s Hospital.
Dr. Kuritzkes has published extensively on antiretroviral therapy and drug resistance in HIV-1 infection. He has chaired several multicenter studies of HIV therapy and previously chaired the AIDS Clinical Trials Group. He has served on numerous NIH committees, including as a member of the NIH Office of AIDS Research Advisory Council. He is a former member of the Department of Health and Human Services panel on guidelines for antiretroviral therapy and a past Chair of the HIV Medicine Association Board of Directors. He has been a member of several editorial boards, and serves as an Associate Editor of the Journal of Infectious Diseases. His research interests focus on HIV therapeutics, antiretroviral drug resistance, HIV eradication and more recently, COVID-19.
At the completion of this educational session, learners will:
1. Be aware of the outcomes of treatment with CAB/RPV LA.
2. Understand the risks for failure of CAB/RPV LA.
3. Appreciate the virological basis for increased risk of CAB resistance in HIV subtype A6.
Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity.
- Dr. James F. Braun (Course Director) has no relevant financial relationships to disclose.
- Dr. William M. Valenti (Moderator) has no relevant financial relationships to disclose.
- Dr. Daniel R. Kuritzkes (Presenter) has had the following personal financial relationships in the past 24 months with manufacturers of the products or services that may be presented in this CME activity: Consultant to: AbbVie, Gilead, GlaxoSmithKline, Janssen, Merck, and ViiV; Research Support from: Gilead, Merck, and ViiV. Dr. Kuritzkes will submit their slides in advance for adequate peer review and will support their presentation and clinical recommendations with the best available evidence from the medical literature. All relevant financial relationships have been mitigated.
Download Article PDF/Slides